Weekly docetaxel and bortezomib in the treatment of patients with advanced hormone refractory prostate cancer (HRPC): A Minnie Pearl Cancer Research Network phase II trial.

被引：0
|
作者：
Meluch, AA
Spigel, DS
Greco, FA
Barton, JH
Messina, G
Gould, B
Rovito, MA
Hainsworth, JD
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[2] Wellstar Hlth Syst Canc Res, Marietta, GA USA
[3] Consultants Med Oncol & Hematol, Drexel Hill, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：436S / 436S
页数：1
相关论文
共 50 条
  • [41] Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: A phase II trial of the Minnie Pearl Cancer Research Network
    Hainsworth, JD
    Burris, HA
    Morrissey, LH
    Thomas, M
    Erland, JB
    Butts, JA
    Joseph, G
    Kalman, L
    Greco, FA
    CANCER JOURNAL, 2000, 6 (03): : 151 - 156
  • [42] Phase II randomized trial of docetaxel plus estramustine (BE) versus docetaxel (D) in patients (pts) with hormone-refractory prostate cancer (HRPC): A final report.
    Eymard, JC
    Joly, F
    Priou, F
    Zannetti, A
    Ravaud, A
    Kerbrat, P
    Mousseau, M
    Paule, B
    Touze, F
    Ecstein-Fraisse, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 407S - 407S
  • [43] A phase I/II study of docetaxel and atrasentan in men with metastatic hormone-refractory prostate cancer (HRPC)
    George, DJ
    Gockerman, JP
    Petros, W
    Haley, S
    Franklin, AD
    Creel, PA
    Turner, AG
    Sleep, D
    Hurwitz, HI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 419S - 419S
  • [44] Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer
    Copur, MS
    Ledakis, P
    Lynch, J
    Hauke, R
    Tarantolo, S
    Bolton, M
    Norvell, M
    Muhvic, J
    Hake, L
    Wendt, J
    SEMINARS IN ONCOLOGY, 2001, 28 (04) : 16 - 21
  • [45] Paclitaxel/carboplatin/etoposide (PCE) therapy for advanced poorly differentiated neuroendocrine (PDNE) carcinoma: A Minnie Pearl Cancer Research Network phase II trial.
    Miranda, FT
    Spigel, DR
    Hainsworth, JD
    Thompson, DS
    Yardley, DA
    Burris, HA
    Litchy, S
    Shrader, M
    Hon, JK
    Corso, SW
    Greco, FA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 322S - 322S
  • [46] A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)
    Breitz, H. B.
    Roman, L. A.
    Karlov, P. A.
    Cheporov, S. V.
    Lopatkin, N. D.
    Baker, G. S.
    Karlin, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel
    Chi, K. N.
    Beardsley, E. K.
    Venner, P. M.
    Eigl, B. J.
    Hotte, S. J.
    Ko, Y.
    Saad, F.
    Winquist, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer
    Hainsworth, JD
    Burris, HA
    Erland, JB
    Thomas, M
    Greco, FA
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) : 2164 - 2168
  • [49] Phase II study of single agent gemcitabine in patients with hormone refractory prostate cancer (HRPC).
    Nilsson, S
    Holmberg, M
    Ljung, G
    Pettersson-Skjold, D
    Blom, R
    Ullén, A
    Westberg, R
    Nilsson, I
    Lennernas, B
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 432S - 432S
  • [50] A multicentric phase II randomized trial of docetaxel (D) plus estramustine (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC).
    Caffo, O.
    Sava, T.
    Comploj, E.
    Fariello, A.
    Zustovich, F.
    Valduga, F.
    Frisinghelli, M.
    Segati, R.
    Sacco, C.
    Perin, A.
    Pappagallo, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 247S - 247S
12345